Stock Fundamentals

Company Information

Company Name
Guardant Health Inc
Sector
Healthcare
Industry
Diagnostics & Research
Exchange
NASDAQ
ISIN: US40131M1099
CIK: 0001576280
CUSIP: 40131M109
Currency: USD
Full Time Employees: 2,490
Phone: 855 698 8887
Fiscal Year End: December
IPO Date: Oct 04, 2018
Description:

Guardant Health, Inc., a precision oncology company, provides blood and tissue tests, and data sets in the United States and internationally. The company offers Guardant360 CDx test, a liquid biopsy test for tumor mutation profiling; Guardant360 Liquid test, which measures 740+ genes and supports all guideline-recommended biomarkers; Guardant Reveal test, a blood test that utilizes circulating tumor DNA to detect cancer at the molecular level; and Guardant360 Tissue test, a molecular profiling test for tumor tissue that provides genomic, transcriptomic, and epigenomic insights. It also provides Shield blood test for colorectal cancer screening in adults. In addition, the company offers GuardantINFINITY test that provides insights into the complexities of tumor molecular profiles and immune response to advance cancer research and therapy development; GuardantOMNI test covers 500 genes, including genes associated with homologous recombination repair deficiency and biomarkers for immuno-oncology applications; GuardantINFORM, which provides longitudinal biological insight into tumor evolution alongside longitudinal clinical outcomes; and GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies. Further, it provides Smart Platform, which delivers multiomic insights leveraging genomic, epigenomic, and RNA-based data that are scalable from research to the clinic. Additionally, the company offers development services, including companion diagnostic development and regulatory approval, clinical study setup, monitoring and maintenance, testing development and support, technologies licensing, and kit fulfillment and delivery of Shield screening tests. It has a strategic collaboration with Nuvalent, Inc. for oncology drug development. The company was incorporated in 2011 and is headquartered in Palo Alto, California.

Address:

3100 Hanover Street, Palo Alto, CA, United States, 94304

Directors & Officers

Name Title Year Born
Dr. Helmy Eltoukhy Ph.D. Co-Founder, Co-CEO & Chairman 1979
Dr. AmirAli Talasaz Ph.D. Co-CEO & Director 1980
Mr. Michael Bell Chief Financial Officer 1969
Dr. Darya Chudova Chief Technology Officer 1974
Mr. John G. Saia J.D. Chief Legal Officer & Corporate Secretary 1973
Mr. Andy Ament Senior Vice President of Operations NA
Mr. Kumud Kalia Chief Information Officer 1966
Zarak Khurshid Vice President of Investor Relations NA
Ms. Gulshan Shaver J.D. Senior VP of Legal Affairs & Chief Compliance Officer NA
Ms. Jennifer Higgins Senior Vice President of Public Affairs NA

Insider Trading

Date Insider Name Title Transaction Type Shares Price Value
Apr 16, 2026 Musa Tariq N/A Sale 116.00 $84.83 $9.84K
Apr 06, 2026 Terilyn J Monroe N/A Sale 3.83K $92.68 $355.15K
Mar 18, 2026 Musa Tariq N/A Sale 348.00 $88.09 $30.66K
Mar 16, 2026 Michael Brian Bell N/A Sale 3.00K $87.04 $261.12K
Mar 06, 2026 Medina Manuel Hidalgo N/A Sale 1.30K $91.54 $119.00K
Jan 21, 2026 Terilyn J Monroe N/A Sale 8.57K $114.09 $977.87K
Jan 07, 2026 Terilyn J Monroe N/A Sale 10.03K $112.08 $1.12M
Dec 17, 2025 Musa Tariq N/A Sale 116.00 $101.46 $11.77K
Dec 15, 2025 Darya Chudova N/A Sale 5.45K $104.04 $567.12K
Dec 15, 2025 Helmy Eltoukhy N/A Sale 90.57K $103.82 $9.40M
Dec 08, 2025 Medina Manuel Hidalgo N/A Sale 1.25K $105.00 $131.25K
Dec 08, 2025 Darya Chudova N/A Sale 9.27K $106.00 $982.73K
Dec 08, 2025 Amirali Talasaz N/A Sale 100.00K $105.05 $10.51M
Dec 08, 2025 Darya Chudova N/A Sale 13.66K $105.04 $1.44M
Dec 05, 2025 Chris Freeman N/A Sale 31.45K $103.07 $3.24M
Dec 05, 2025 Ian T Clark N/A Sale 28.61K $107.19 $3.07M
Dec 05, 2025 Michael Brian Bell N/A Sale 80.36K $103.14 $8.29M
Dec 01, 2025 Terilyn J Monroe N/A Sale 55.17K $105.97 $5.85M
Nov 21, 2025 Sheldon Whitehouse N/A Purchase N/A $105.42 N/A
Nov 19, 2025 Musa Tariq N/A Sale 116.00 $96.25 $11.17K

Institutional Holders

Holder Name Shares Date Reported % Out Value % Change
Vanguard Group Inc 12.16M Dec 31, 2025 9.17% $0.02 2.12%
BlackRock Inc 11.55M Mar 31, 2026 8.71% $0.02 2.09%
T. Rowe Price Associates, Inc. 7.02M Mar 31, 2026 5.30% $0.08 24.62%
Vanguard Portfolio Management, LLC 5.84M Mar 31, 2026 4.40% $0.03 0.00%
Vanguard Capital Management, LLC 5.62M Mar 31, 2026 4.24% $0.01 0.00%
Amvescap Plc. 4.95M Mar 31, 2026 3.73% $0.07 -6.95%
The Goldman Sachs Group Inc 4.44M Mar 31, 2026 3.35% $0.05 68.81%
Two Sigma Investments LLC 4.23M Mar 31, 2026 3.19% $0.32 94.74%
FMR Inc 4.12M Mar 31, 2026 3.10% $0.02 71.76%
Baillie Gifford & Co Limited. 3.86M Mar 31, 2026 2.91% $0.36 -21.08%
Geode Capital Management, LLC 3.51M Mar 31, 2026 2.65% $0.02 9.19%
Capital Research & Mgmt Co - Division 3 3.48M Mar 31, 2026 2.63% $0.08 -1.34%
Franklin Resources Inc 3.45M Mar 31, 2026 2.60% $0.08 2.58%
Deep Track Capital, LP 3.34M Mar 31, 2026 2.52% $5.04 19.22%
State Street Corp 2.88M Mar 31, 2026 2.18% $0.01 3.18%
Fuller & Thaler Asset Management Inc 2.55M Mar 31, 2026 1.92% $0.79 -47.78%
Two Sigma Advisers, LLC 2.38M Dec 31, 2025 1.80% $0.47 12.76%
Eventide Asset Management, LLC 2.36M Mar 31, 2026 1.78% $3.61 -5.92%
PIER 88 INVESTMENT PARTNERS LLC 2.06M Mar 31, 2026 1.55% $0.71 30,064.22%
AllianceBernstein L.P. 1.91M Mar 31, 2026 1.44% $0.06 0.23%

Shares Statistics

Shares Outstanding: 132.60M
Shares Float: 127.84M
% Insiders: 402.40%
% Institutions: 10,599.80%
Short % Float: 9.55%

Fund Holdings

Rank Holder Name Shares Held % of Shares Change Date Reported
1 Vanguard Total Stock Mkt Idx Inv 3.97M 2.99% ▲ 0.25% Apr 30, 2026
2 iShares Russell 2000 ETF 2.97M 2.24% ▲ 0.93% May 29, 2026
3 Vanguard Small Cap Index 2.87M 2.17% ▼ 0.21% Apr 30, 2026
4 Franklin DynaTech A 1.75M 1.32% ▲ 0.00% Apr 30, 2026
5 Franklin Innovation Composite 1.75M 1.32% ▲ 0.00% Mar 31, 2026
6 Vanguard US Growth Investor 1.72M 1.29% ▼ 31.77% Mar 31, 2026
7 FullerThaler Behavioral Small-Cap Growth 1.68M 1.27% ▲ 1.26% Mar 31, 2026
8 FullerThaler Behavioral Sm-Cp Gr R6 1.64M 1.24% ▲ 7.23% Mar 31, 2026
9 Vanguard Small Cap Growth Index Inv 1.61M 1.21% ▼ 0.10% Apr 30, 2026
10 Eventide Gilead N 1.61M 1.21% ▼ 6.60% Mar 31, 2026

Valuation Metrics

Enterprise Value: $21.82B
Trailing P/E: 0.00
Forward P/E: 0.00

Financial Highlights

Market Cap: $21.22B
EBITDA: $-408.16M
Book Value: $-1.38
Earnings/Share: $-3.41
Profit Margin: -40.10%
Operating Margin: -40.23%
ROA (TTM): -17.15%
ROE (TTM): -4,584.47%
Revenue (TTM): $1.08B
Revenue/Share (TTM): $8.49
Earnings Growth (YOY): 0.00%
Revenue Growth (YOY): 48.30%

Stock Price History

1 Year Price History

2 Years Price History

5 Years Price History

10 Years Price History

Financial Charts

Revenue & Net Income (Yearly)

Revenue & Net Income (Quarterly)

Operating Expenses (Yearly)

Operating Expenses (Quarterly)

Balance Sheet (Yearly)

Balance Sheet (Quarterly)

Assets Breakdown (Yearly)

Assets Breakdown (Quarterly)

Liabilities Breakdown (Yearly)

Liabilities Breakdown (Quarterly)

Earnings Per Share (EPS) History

Financial Ratios

Balance Sheet (Yearly)

Financial Ratios

Date Current Ratio Debt/Equity Debt/Assets Interest Coverage Debt/EBITDA
2025-12-31 4.84x -15.42x 1.05x -111.96x -4.10x
2024-12-31 4.68x -8.39x 1.09x -171.87x -3.00x
2023-12-31 6.54x 7.36x 0.91x -219.06x -2.70x
2022-12-31 6.17x 19.26x 0.96x -211.24x -1.89x
2021-12-31 5.72x 1.78x 0.71x -159.49x -3.19x
2020-12-31 28.27x 0.63x 0.40x -53.49x -3.61x
2019-12-31 8.21x 0.01x 0.12x -69.75x -0.13x
2018-12-31 9.99x 0.00x 0.11x -74.29x 0.00x
2017-12-31 12.38x 0.00x 0.10x -28.35x -0.01x
2016-12-31 7.22x 0.21x 0.32x -14.53x -0.42x

📦 Raw API Data (JSON Explorer)

Watchlist

0

No stocks in watchlist

Assistant

×
Hello! I'm your AI assistant. I have access to the financial data on this page. Ask me anything about GH.US!